Houston Methodist opened a new tech hub in the Ion this week. Photo by Shannon O’Hara/Ion

Photos: Houston hospital opens tech hub in the Ion

innovation outpost

A Houston hospital has opened an innovation outpost in the Ion this week in order to showcase health tech innovation and connect with Houston innovators.

The Houston Methodist Tech Hub at Ion hub has officially opened. The 1,200-square-foot space was created in addition to the Center for Innovation Technology Hub that's in Houston Methodist’s flagship location in the Texas Medical Center, which opened in February 2020.

The new space, located on the lower level of the Ion, exists to serve as a common ground for innovators across industries to promote collisions and innovation, as well as interaction with Houston Methodist team members

“Our new Tech Hub at Ion supports not only our commitment to the Houston innovation community but also to the rapidly shifting healthcare industry,” Michelle Stansbury, vice president of innovation and IT applications at Houston Methodist, says in a statement. “We know we can’t solve the healthcare challenges of the future if we confine ourselves within our hospital walls or even within our own industry.

"We look forward to the collaborative space our new Tech Hub will provide and the future programming opportunities we can create together to inspire, challenge, and foster a spirit of innovation in our city.”

The new hub, according to the news release, also will host educational events, reverse pitch sessions, and more. Visitors can schedule a time to view the space or connect with the Houston Methodist innovation team by filling out a form online.

The hub, which was originally announced last year, is the latest partner to open within the Ion's space. Earlier this year, the organization announced other new tenants.

“Houston Methodist’s space at the Ion opens up even more opportunities for our start-up and entrepreneur community to embed and gain exposure to the latest innovations in health care, health technology, and digital health,” Jan E. Odegard, executive director of Ion, says. “This partnership and opportunity provided by Houston Methodist, a leading healthcare organization in the country, is a testament to the ecosystem we’re building and the talent within our building. Furthermore, Houston Methodist’s approach and appetite for cross-industry innovation and collaboration meshes seamlessly with the Ion’s ongoing plans to support Houston’s growing innovation community in industries and fields that will change the world.”

Both of Houston Methodist's tech hubs will showcase its latest technologies its implementing in its hospital system, including the "hospital of the future" it's building out in Cypress.

Collaborative effort

Photo by Shannon O’Hara/Ion

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.